



Ocular Therapeutix Announces Closing of Initial Public Offering

July 30, 2014

BEDFORD, Mass.--(BUSINESS WIRE)--Jul. 30, 2014-- Ocular Therapeutix (Nasdaq: OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, announced today the closing of its initial public offering of 5,000,000 shares of its common stock at a public offering price of \$13.00 per share, resulting in net proceeds of approximately \$60.5 million after deducting underwriting discounts and commissions, and estimated offering expenses. All of the shares of common stock in the offering were sold by Ocular Therapeutix.

Morgan Stanley, Cowen and Company and RBC Capital Markets acted as joint book-running managers for the offering. Oppenheimer & Co. acted as a co-manager.

A copy of the final prospectus relating to the offering may be obtained from Morgan Stanley & Co. LLC, attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014; Cowen and Company, LLC, c/o Broadridge Financial Services, attention: Prospectus Department, 1155 Long Island Avenue, Edgewood, NY, 11717; or RBC Capital Markets, LLC, attention: Equity Syndicate, Three World Financial Center, 200 Vesey Street, 8th Floor, New York, NY 10281-8098.

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on July 24, 2014. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities, in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Ocular Therapeutix

Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. Ocular Therapeutix's lead product candidates are in Phase 3 clinical development for post-surgical ocular inflammation and pain and Phase 2 clinical development for glaucoma, ocular hypertension and allergic conjunctivitis. The Company is also evaluating sustained-release injectable anti-VEGF drug depots for back-of-the-eye diseases. Ocular Therapeutix's first product, ReSure[®] Sealant, was approved by the U.S. Food and Drug Administration in January 2014 to seal corneal incisions following cataract surgery.

Source: Ocular Therapeutix, Inc.

Investors:

Ocular Therapeutix, Inc.

Brad Smith

Chief Financial Officer

bsmith@ocutx.com

or

Burns McClellan on behalf of Ocular Therapeutix

Kimberly Minarovich, 212-213-0006

kminarovich@burnsmc.com

or

Media:

Scott Corning

Vice President of Sales and Marketing

scorning@ocutx.com